We are dedicated to developing tomorrow’s drugs against oxidative stress, helping millions of people to a better life by preventing and treating serious kidney diseases. ROSgard, our biological drug candidate, mimics the body’s own powerful defense system against oxidative stress. Designed with a natural “homing” to the kidneys, ROSgard prevents kidney damage by protecting, cleaning and repairing the exposed cells and tissues.

A phase 1 program including four separate studies was completed during the summer of 2021. Learn more about the clinical development of ROSgard.

Read more

CLINICAL STUDIES

ROSgard, our drug candidate, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Read more

ROSgard™

Acute kidney injury is a large market. The estimated annual value is USD 6.3 bn in the USA and GBP 500 mn in the UK.

Read more

INVESTOR RELATIONS

Press releases
  • 26 Apr 2022  ·  Regulatory information

    Guard Therapeutics recruits new Head of CMC

    Read more
  • 13 Apr 2022

    Guard Therapeutics provides in-depth information on phase 2 clinical trial

    Read more
  • 07 Apr 2022

    First patient has been dosed in Guard Therapeutics' Phase 2 clinical trial of ROSgard

    Read more
  • 12 Jan 2022

    Guard Therapeutics receives approval to expand the global phase 2 study of ROSgard to Canada

    Read more
Show more
Calendar & reports
  • 23 Aug 2022

    Interim report April-June 2022

    Read more
  • 16 Nov 2022

    Interim report July-September 2022

    Read more
  • 22 Feb 2023

    Year-end report 2022

    Read more
Reports, presentations & in media
  • 27 Apr 2022 / Presentation

    Life Science Investor Conference 27 April 2022 (Copenhagen, Dennmark)

    Read more
  • 02 Dec 2021 / Presentation

    Erik Penser Banks Temadag - Life Science

    Read more
  • 01 Feb 2021 / In media

    (in Swedish) Rutger Arnhults och EQT-veteranens läkemedelsbolag får tyskt klartecken

    Read more
Show more